Policy & Regulation
CHMP backs Gilead's Trodelvy-Keytruda combination for first-line metastatic triple-negative breast cancer
24 July 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recom...
Active Biotech doses first patient in amended tasquinimod myelofibrosis study
24 July 2026 - Swedish biotechnology company Active Biotech AB (STO:ACTI) announced on Friday that the first patient has been dosed in the amended Phase Ib/II clinical study of tasquinimod in patients...
Ipsen's Phase III BOLD trial misses primary endpoint in biliary atresia
24 July 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) disclosed on Friday that its Phase III BOLD trial evaluating Bylvay (odevixibat) versus placebo in patients with ...
Sanofi ends atopic dermatitis development for amlitelimab
24 July 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) said on Friday that it will discontinue the clinical development of amlitelimab, an OX40-ligand monoclonal antibo...
ArkBio completes Australian dosing in Phase I trial of influenza AFC drug AK0406
24 July 2026 - Chinese biotechnology company Shanghai Ark Biopharmaceutical Co Ltd ('ArkBio') announced on Thursday that all cohorts of healthy volunteers have been dosed in an Australian Ph...
Lilac Biosciences and Soin Neuroscience publish clinical review on RNA biomarkers for neuropathic pain
24 July 2026 - Lilac Biosciences Inc, a life sciences company spun out of the Giuliani RNA Center at Brown University, and medical device company Soin Neuroscience announced on Thursday the publicatio...